Dermatology
Latest News
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?
“They’re very fast-acting, effective,” and result in a large improvement over steroids, Dr. Jashin Wu said.
Latest News
Topical Treatment Provides a Noninvasive Option for Pyogenic Granuloma in Children
Several case reports about the use of the topical form of timolol, a nonselective beta-adrenergic antagonist, for PG have been published.
Latest News
Managing Vitiligo: Combination Therapies, New Treatments
The level of vitiligo disease activity drives medical management.
Latest News
Metformin Led to Improvements in Women with Central Centrifugal Cicatricial Alopecia
Metformin led to significant clinical improvement in eight patients with CCCA, in the case series.
From the Journals
Analysis of Colchicine’s Drug-Drug Interactions Finds Little Risk
Changes in colchicine pharmacokinetics caused by drug-drug interactions did not result in meaningful changes in its safety and effectiveness,...
From the Journals
What’s Causing Raynaud Phenomenon Severity to Rise With High Temperatures?
Both extreme heat and cold were tied to more severe episodes of Raynaud phenomenon in a study of participants with systemic sclerosis.
Latest News
Focusing on Value in Social Media Posts
One review noted that social media ranks as the sixth top factor for a patient deciding whether to have a laser procedure.
Latest News
Study Indicates Skin Cancer Risk Elevated Among Veterans
“Public health measures seeking to address veteran healthcare differences could emphasize primary preventive strategies to mitigate risk,” the...
Latest News
Black Children With Vitiligo at Increased Risk for Psychiatric Disorders: Study
Researchers conducted a retrospective, single-center, case-control study of 327 Black children with vitiligo and 981 matched controls without...
Latest News
Neurofibromatosis: What Affects Quality of Life Most?
“To develop effective therapeutics, meaningful clinical outcomes that are tied with improvement in QoL for persons with NF1 must be clearly...
Feature
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal Intervention
OIG reports showed a spike in ustekinumab costs for patients in Medicare Part D. Experts said Inflation Reduction Act changes in Medicare drug...